Viromed Medical AG, a German medical technology company specializing in cold plasma technology, published its half-year report for 2026 on September 28, revealing advances in product development and market launch alongside a confirmed full-year guidance. The company, listed on the stock exchange since October 2022, reported consolidated revenue of EUR 2.5 million for the first half of 2026, a slight increase from EUR 2.4 million in the same period of 2025. However, net loss widened to EUR 1.1 million from EUR 0.8 million, driven by expenses related to the comprehensive PulmoPlas® study and the approval and market launch of ViroCAP® med. Equity rose 43.9% to EUR 9.5 million, resulting in a strengthened equity ratio of 67.6%.
During the reporting period, Viromed continued preclinical development of PulmoPlas®, initiated OEM production of ViroCAP® for HELLMUT RUCK GmbH, and concluded an exclusive sales partnership with NEBU-TEC for veterinary applications of PulmoPlas®. The company also successfully completed the conformity assessment procedure for ViroCAP® med as a Class IIa medical device under the EU Medical Device Regulation, receiving the official approval certificate in early July 2026, which enables sales to begin. Additionally, Viromed was granted a research allowance of EUR 550,000 for research and development projects in cold plasma technology. The planned acquisition of relyon plasma GmbH remained a key strategic focus.
CEO Uwe Perbandt commented, “We successfully continued developing our products in the first half of the year while also making important progress in preclinical research. The planned publication of the study results in a renowned scientific journal will further strengthen the scientific evidence supporting our cold plasma technology. This will give us greater visibility and a solid foundation for the next steps in the further development and marketing of our products.”
Financing during the period came primarily through a EUR 2.7 million loan from Perbamed Invest GmbH, which was reviewed and approved by the supervisory board and the company’s tax advisor. For the 2026 financial year, Viromed expects a significant increase in consolidated revenue and net income, confirming its full-year guidance as adjusted on May 8, 2026. The half-year financial statements are available on the Viromed Medical AG website.
The news matters because it demonstrates Viromed’s progress in bringing cold plasma technology to market, a novel approach with potential applications in wound care and veterinary medicine. The approval of ViroCAP® med and the sales partnership with NEBU-TEC could drive revenue growth and expand the company’s footprint beyond the DACH region. The strengthened equity ratio and confirmed guidance signal financial stability and confidence, which may attract investors. For the medical technology industry, Viromed’s advances underscore the growing interest in cold plasma as a therapeutic tool. The original release is available on www.newmediawire.com.
